Relapsed Cancer Clinical Trials

10 recruiting

Frequently Asked Questions

Common questions about Relapsed Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled49 locationsNCT06634589
Recruiting
Phase 2

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 2

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Multiple MyelomaRelapsed CancerRefractory Multiple Myeloma
Massachusetts General Hospital50 enrolled2 locationsNCT05922501
Recruiting
Phase 2

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Refractory CancerRelapsed CancerLarge Cell Lymphoma, Diffuse
Dipenkumar Modi32 enrolled4 locationsNCT05852717
Recruiting
Phase 4

Plan Development for Giving Teclistamab in the Outpatient Setting

Multiple MyelomaRefractory CancerRelapsed Cancer
University Health Network, Toronto15 enrolled1 locationNCT06251076
Recruiting

Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma

Relapsed CancerGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
University Hospital, Bordeaux40 enrolled1 locationNCT06430424
Recruiting

Precision Medicine for Every Child With Cancer

Refractory CancerChildhood CancerChildhood Brain Tumor+3 more
Australian & New Zealand Children's Haematology/Oncology Group3,500 enrolled11 locationsNCT05504772
Recruiting
Phase 2

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Refractory CancerClassical Hodgkin LymphomaRelapsed Cancer
University Health Network, Toronto37 enrolled1 locationNCT04510636